Skip to main content

Table 3 Metabolic profile of HIV-infected patients segregated according to HCV co-infection and antiretroviral therapy

From: Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection

  Non-HCV co-infected group HCV co-infected group
  Untreated NNRTI PI Untreated NNRTI PI
  ( n = 19) ( n = 32) ( n = 25) ( n = 32) ( n = 44) ( n = 39)
FASN, μg/L 5.14 (2.10) 7.40 (1.81) 4.15 (1.00) 20.01 (4.0) 8.64 (1.51) b 11.75 (2.41) a
NEFA, mmol/L 0.53 (0.07) 0.63 (0.07) 0.77 (0.1) 0.65 (0.06) 0.67 (0.05) * 0.52 (0.04)
Glucose, mmol/L 5.21 (0.20) 5.77 (0.29) * 5.09 (0.09) 5.13 (0.13) 5.62 (0.19) a 5.21 (011)
Insulin, pmol/L 41.91 (7.1) 70.74 (13.4) a 62.23 (8.6) a 71.35 (11.2) 103.2 (19.8) 72.24 (10.7)
HOMA-IR 0.80 (0.16) 1.38 (0.27) a 1.14 (0.16) 1.41 (0.25) 2.06 (0.42) 1.36 (0.21)
Cholesterol, mmol/L 4.59 (0.24) 5.34 (0.23) a,* 6.10 (0.28) c 4.41 (0.19) 4.67 (0.23) 4.7 (0.16)
HDL-cholesterol, mmol/L 1.18 (0.09) 1.30 (0.12) 1.18 (0.10) 1.17 (0.07) 1.20 (0.05) * 1.09 (0.6)
LDL-cholesterol, mmol/L 2.69 (0.22) 3.10 (0.20) * 3.59 (0.23) a 2.57 (0.15) 2.54 (0.18) 2.70 (1.15)
Triglyceride, mmol/L 1.57 (0.29) 2.60 (0.44) a 4.87 (1.50) b 2.99 (1.71) 2.35 (0.36) a 2.17 (0.22) b
Apolipoprotein AI, g/L 1.39 (0.06) 1.43 (0.07) 1.34 (0.06) 1.33 (0.06) 1.45 (0.04) * 1.32 (0.04)
Alanine aminotransferase, μKat/L 0.52 (0.10) 0.57 (0.11) 0.45 (0.06) 1.16 (0.16) 0.91 (0.11) 0.69 (0.07) a
Aspartate aminotransferase, μKat/L 0.45 (0.07) 0.45 (0.04) 0.41 (0.08) 1.02 (0.13) 0.94 (0.14) 0.69 (0.07) a
  1. Values are the mean and the standard error of the mean (S.E.M.).
  2. HOMA-IR is homeostasis model assessment-estimated insulin resistance; NEFA indicates non-esterificated fatty acids; NNRTI: non-nucleoside analogues reverse transcriptase inhibitors; PI: protease inhibitors;
  3. a P < 0.05, b P < 0.01 and c P < 0.001 vs untreated patients of the corresponding group; * P < 0.05 with respect to PI-treated patients in the corresponding group